Context TherapeuticsCNTX
CNTX
About: Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Employees: 9
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
100% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]
24% more funds holding
Funds holding: 34 [Q2] → 42 (+8) [Q3]
3.05% less ownership
Funds ownership: 78.63% [Q2] → 75.58% (-3.05%) [Q3]
6% less capital invested
Capital invested by funds: $118M [Q2] → $111M (-$7.05M) [Q3]
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
488%
upside
Avg. target
$7.50
635%
upside
High target
$9
782%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 25% 1-year accuracy 38 / 150 met price target | 782%upside $9 | Buy Initiated | 25 Nov 2024 |
HC Wainwright & Co. Emily Bodnar 17% 1-year accuracy 26 / 150 met price target | 488%upside $6 | Buy Reiterated | 23 Sept 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
Expands pipeline of T cell engaging bispecific antibodies through acquisitions of CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody
Neutral
GlobeNewsWire
1 month ago
Context Therapeutics to Participate in Upcoming Investor Conferences in November
PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced that the Company will participate in the following investor conferences in November:
Neutral
GlobeNewsWire
2 months ago
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company's clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.
Neutral
GlobeNewsWire
2 months ago
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales Context anticipated IND filing for BA3362 in mid-2026 SAN DIEGO and PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (“BioAtla”) (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (“CAB”) antibody therapeutics for the treatment of solid tumors, and Context Therapeutics Inc. (“Context”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the companies have entered into an agreement under which Context has obtained from BioAtla an exclusive, worldwide license to develop, manufacture and commercialize BA3362, BioAtla's Nectin-4 x CD3 TCE.
Negative
Zacks Investment Research
3 months ago
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?
Here is how Context Therapeutics Inc. (CNTX) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Neutral
GlobeNewsWire
3 months ago
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy The appointments of Dr. Karen Smith and Dr. Luke Walker to the Board bring extensive operational and clinical development experience to support corporate and pipeline strategy
Negative
Zacks Investment Research
3 months ago
Are Medical Stocks Lagging Context Therapeutics Inc. (CNTX) This Year?
Here is how Context Therapeutics Inc. (CNTX) and Co-Diagnostics, Inc. (CODX) have performed compared to their sector so far this year.
Neutral
GlobeNewsWire
4 months ago
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
Announced acquisition of CT-95, a mesothelin x CD3 bispecific antibody Claudio Dansky Ullmann, M.D. named Chief Medical Officer Cash and cash equivalents of $101.5 million as of June 30, 2024 PHILADELPHIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the second quarter ended June 30, 2024, and reported on recent business highlights.
Neutral
GlobeNewsWire
4 months ago
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
Company announces appointments of Dr. Claudio Dansky Ullmann as CMO and Ms. Karen Andreas as VP, Clinical Operations
Positive
Seeking Alpha
5 months ago
Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline
Context Therapeutics Inc.'s acquisition of CT-95, targeting MSLN expressing solid tumors, brings another shot on goal for its pipeline of T cell engagers. CTIM-76 is another T cell engager in the pipeline; however, it is being developed to go after oncofetal protein CLDN6, which is only highly expressed in embryonic tissue. With both phase 1 studies of CT-95 and CTIM-76 underway soon, it is highly likely that preliminary data from both trials could be released in 2025.
Charts implemented using Lightweight Charts™